


Breast					
Protocol # Title	Local Investigator	Primary In/Ex Criteria	Primary Purpose	Status	Accrual to Date
S1703 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer	Arekapudi	Must be receiving or plan to receive first-line systemic treatment for metastatic disease; must be registered to Step 1 between 14 days prior to and 60 days after start of 1st line systemic treatment for metastatic disease	Health Services Research	Open to Accrual	2
A012103 OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy	Arekapudi	T1cN1-2 or T2-4N0-2 TNBC who achieve pCR after neoadjuvant chemo	Treatment	Open to Accrual	1
NRG-CC011 Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial	Arekapudi	Stage I-III, non-metastatic breast cancer participants ≥ 6 months to 5 years post-treatment	Prevention	Open to Accrual	8
NRG-CC015 Harnessing E-Mindfulness Approaches for Living After Breast Cancer --- HEAL-ABC	Aldred	Advanced/Metastatic HR+ HER2 -disease, first line treatment	Prevention	Open to Accrual	0
BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Arekapudi	Premenopausal; resected ER-positive/HER2-negative intermediate risk, early-stage breast cancer	Treatment	Open to Accrual	0
Pfizer C4391024 An Interventional, Open-Label, Randomized, Multicenter Phase III Study of PF-07220060 Plus Letrozole Compared to CDK4/6 Inhibitor Plus Letrozole in Participants Over 18 Years of Age with Hormone Receptor (HR)-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advanced/Metastatic Disease (Fourlight-3)	Arekapudi	Advanced/Metastatic HR+ HER2 -disease, first line treatment	Treatment	Open to Accrual	0
GI					
GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Dr. Shahidi	Arekapudi	Stage IIIA or IIIB, resection within 60 days	Treatment	Open to Accrual	0
Heme					
S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study	Arekapudi	Newly Diagnosed, Early Stage, Asymptomatic, High-Risk CLL/SLL	Treatment	Open to Accrual	1

Protocol # / Title	Local Investigator	Primary In/Ex Criteria	Primary Purpose	Status	Actual/Planned Accrual	Notes
Breast						
A012303 ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade	TBD	T1c-T3 and N0-N1 (except cT3N1 tumors, which are NOT eligible); HER 2+, pCR after NA treatment	Treatment	Pending SIV	9/1524	
Lung						
LungMAP Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	TBD	Stage IV or recurrent/progressive NSCLC	Screening	Pending SIV		
UCDCC323 A RANDOMIZED TRIAL OF RISK-ADAPTED, PROTEOMIC-GUIDED SYSTEMIC THERAPY FOR PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) 	TBD	Stage IV or IIIC NSCLC, First line treatment	Treatment	Pending SIV		
Multiple						
UCDCC304 Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients with Select Solid Malignancies Being Treated with Standard of Care Checkpoint Inhibitor-Based Therapy	TBD	Must have NSCLC, RCC, melanoma, CRC, TNBC or other solid tumor malignancy appropriate to receive SOC Cpi-based therapy	Treatment	Pending SIV	24/100	